Impfungen bei gastroenterologischen Erkrankungen und Immunsuppression

Impfungen sind neben der Vermeidung von Infektionsrisiken die effektivste Methode der Vorbeugung schwerwiegender oder potenziell tödlicher Erkrankungen. Dies gilt insbesondere für Patienten, die entweder eine vorbestehende, chronische Erkrankung haben oder durch eine Behandlung nur über ein geschwächtes Immunsystem verfügen. In der Gastroenterologie betrifft dies insbesondere Patienten mit chronischen Lebererkrankungen und chronisch entzündlichen Darmerkrankungen, die eine dauernde medikamentöse Immunsuppression benötigen.

Schlüsselwörter

Lebendimpfstoff - Totimpfstoff - Lebererkrankung - chronisch entzündliche Darmerkrankung - Immunsuppression

• Literatur

• 1 Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013; 15: 300
• 2 Nasir M, Vinsard DG, Wakefield D. et al. The important role of immunization in alcoholic and non-alcoholic chronic liver disease: a population-based study. J Dig Dis 2020; 21: 583-592
• 3 Robert-Koch-Institut. Empfehlungen der ständigen Impfkommission beim Robert Koch Institut 2022. Epid Bull 2022; 4: 65
• 4 Kramer JR, Hachem CY, Kanwal F. et al. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology 2011; 53: 42-52
• 5 Pineton de Chambrun G, Dauchet L, Gower-Rousseau C. et al. Vaccination and risk for developing inflammatory bowel disease: a meta-analysis of case-control and cohort studies. Clin Gastroenterol Hepatol 2015; 13: 1405-1415.e1 quiz e130
• 6 Liles E, Irving SA, Dandamudi P. et al. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine 2021; 39: 3614-3620
• 7 Rahier JF, Magro F, Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-468
• 8 Kucharzik T, Ellul P, Greuter T. et al. ECCO Guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021; 15: 879-913
• 9 Robert-Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) und der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. (DTG) zu Reiseimpfungen. Epid Bull 2022; 14: 1-184
• 10 Buhler S, Jaeger VK, Eperon G. et al. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1. J Travel Med 2020; 27: taaa126
• 11 Farraye FA, Melmed GY, Lichtenstein GR. et al. ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017; 112: 241-258
• 12 Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2019; 13: 229-239
• 13 Paik J. Ozanimod: a review in ulcerative colitis. Drugs 2022; 82: 1303-1313
• 14 Caldera F, Saha S, Wald A. et al. Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci 2018; 63: 1532-1540
• 15 Klunder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet 2018; 57: 977-988
• 16 Namour F, Anderson K, Nelson C. et al. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet 2022; 61: 819-832
• 17 Kawalec P, Sladowska K, Malinowska-Lipien I. et al. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 2018; 14: 15-29
• 18 Zhang J, Xie F, Delzell E. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-49
• 19 Robert-Koch-Institut. Impfquoten von Kinderschutzimpfungen in Deutschland – aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epid Bull 2022; 48: 6-29
• 20 Belle A, Baumann C, Bigard MA. et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015; 27: 877-881
• 21 Jackson S, Lentino J, Kopp J. et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 2018; 36: 668-674
• 22 Vesikari T, Finn A, van Damme P. et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs. a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open 2021; 4: e2128652
• 23 Vesikari T, Langley JM, Segall N. et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021; 21: 1271-1281
• 24 Mallet V, Beeker N, Bouam S. et al. Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020. J Hepatol 2021; 75: 848-855
• 25 Iavarone M, DʼAmbrosio R, Soria A. et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020; 73: 1063-1071
• 26 Wang J, Hou Z, Liu J. et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol 2021; 75: 439-441
• 27 Moon AM, Webb GJ, Garcia-Juarez I. et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatol Commun 2022; 6: 889-897
• 28 Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology 2021; 161: 827-836
• 29 Robert Koch-Institut. STIKO-Empfehlung zur COVID-19-Impfung. Epid Bull 2022; 40: 3-20